Assessing Novavax (NVAX) Valuation After Recent Share Price Momentum And Partnership Shifts

Simply Wall St

Sat, February 14, 2026 at 4:09 PM GMT+9 2 min read

In this article:

NVAX

+3.33%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Context for Novavax after recent share performance

Novavax (NVAX) has drawn fresh attention after a recent move in its share price, with the stock showing a 3.3% one day return alongside gains over the past week, month, and past 3 months.

See our latest analysis for Novavax.

That 3.33% 1 day share price return and 24.82% 3 month share price return come against a longer record where the 1 year total shareholder return is 6.23% and the 5 year total shareholder return reflects a very large decline of 96.87%. Recent momentum is therefore building off a much lower base.

If vaccine news has you looking more broadly at healthcare opportunities, it could be a good time to scan our screener of 25 healthcare AI stocks for fresh ideas.

With Novavax trading at US$8.70 and at around a 48% discount to the current analyst price target, alongside an intrinsic model suggesting an even larger gap, you have to ask: is there real value here, or is the market already pricing in all the future growth?

Most Popular Narrative: 33.6% Undervalued

With Novavax last closing at $8.70 against a narrative fair value of $13.11, the current price sits well below what this framework suggests.

Ongoing cost optimization and the shift to a leaner, partnership focused operational model, with substantial SG&A reductions and Sanofi absorbing additional costs, position Novavax for improved gross and net margins, supporting an accelerated path to sustained profitability and stronger long term earnings.

Read the complete narrative.

The widely followed narrative hinges on how far margins can stretch, how quickly licensing ramps, and what kind of earnings multiple that could support.

Result: Fair Value of $13.11 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on partners like Sanofi and Takeda hitting their milestones, and on COVID-19 vaccine demand not fading faster than analysts currently expect.

Find out about the key risks to this Novavax narrative.

Build Your Own Novavax Narrative

If you are not fully on board with this view or prefer to lean on your own work, you can review the numbers yourself and build a tailored narrative in just a few minutes: Do it your way.

A great starting point for your Novavax research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist with a few focused idea lists that could surface opportunities you have not considered yet.

Story Continues  

Target potential value opportunities by scanning our list of 53 high quality undervalued stocks that pair solid fundamentals with appealing pricing signals.

Strengthen the quality of your holdings by reviewing companies in our solid balance sheet and fundamentals stocks screener (44 results), where financial resilience takes center stage.

Spot under the radar names before they are widely followed by checking out the screener containing 23 high quality undiscovered gems curated from our broader universe.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include NVAX.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info